0001127602-20-018883.txt : 20200604 0001127602-20-018883.hdr.sgml : 20200604 20200604181839 ACCESSION NUMBER: 0001127602-20-018883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200602 FILED AS OF DATE: 20200604 DATE AS OF CHANGE: 20200604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kim Lorence H. CENTRAL INDEX KEY: 0001643746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 20943982 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-06-02 0001682852 Moderna, Inc. MRNA 0001643746 Kim Lorence H. C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Financial Officer Common Stock 2020-06-02 4 M 0 78309 14.22 A 1280819 D Common Stock 2020-06-02 4 M 0 66031 19.15 A 1346850 D Common Stock 2020-06-02 4 M 0 96660 19.15 A 1443510 D Common Stock 2020-06-02 4 S 0 241000 58.30 D 1202510 D Stock Option (Right to Buy) 14.22 2020-06-02 4 M 0 78309 0 D 2028-02-28 Common Stock 78309 587735 D Stock Option (Right to Buy) 19.15 2020-06-02 4 M 0 66031 0 D 2026-08-10 Common Stock 66031 578372 D Stock Option (Right to Buy) 19.15 2020-06-02 4 M 0 96660 0 D 2026-08-10 Common Stock 96660 0 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years). This option is fully vested and exercisable. /s/ Lori Henderson, as Attorney-in-Fact 2020-06-04